Derval O'Carroll
Compliance Officer at INFLARX N.V.
Net worth: - $ as of 31/03/2024
Derval O'Carroll active positions
| Companies | Position | Start | End |
|---|---|---|---|
| INFLARX N.V. | Compliance Officer | 01/01/2022 | - |
| General Counsel | 01/01/2022 | - |
Career history of Derval O'Carroll
Former positions of Derval O'Carroll
| Companies | Position | Start | End |
|---|---|---|---|
| TRAVERE THERAPEUTICS, INC. | General Counsel | 01/12/2015 | 01/12/2017 |
| AMRYT PHARMA PLC | General Counsel | - | - |
Amryt Pharma Holdings Ltd.
 Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | General Counsel | 24/01/2018 | - |
Training of Derval O'Carroll
| University College Dublin | Graduate Degree |
Statistics
International
| United Kingdom | 3 |
| Ireland | 2 |
| United States | 2 |
Operational
| General Counsel | 4 |
| Graduate Degree | 1 |
| Masters Business Admin | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| TRAVERE THERAPEUTICS, INC. | Health Technology |
| INFLARX N.V. | Health Technology |
| Private companies | 2 |
|---|---|
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
Amryt Pharma Plc
 Amryt Pharma Plc Pharmaceuticals: MajorHealth Technology Amryt Pharma Plc operates as a holding company with interests in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The company was founded on July 17, 2019 and is headquartered in Dublin, Ireland. | Health Technology |
- Stock Market
- Insiders
- Derval O'Carroll
- Experience